AnaptysBio Inc (ANAB) Short Interest Update

AnaptysBio Inc (NASDAQ:ANAB) saw a large increase in short interest in December. As of December 29th, there was short interest totalling 1,387,012 shares, an increase of 40.3% from the December 15th total of 988,390 shares. Approximately 9.8% of the company’s shares are sold short. Based on an average daily volume of 280,607 shares, the short-interest ratio is presently 4.9 days.

Several equities research analysts recently commented on ANAB shares. JMP Securities upped their target price on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Zacks Investment Research lowered AnaptysBio from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Royal Bank of Canada upped their target price on AnaptysBio to $108.00 and gave the company an “outperform” rating in a research report on Monday, December 18th. Jefferies Group started coverage on AnaptysBio in a research report on Thursday, November 9th. They set a “buy” rating and a $101.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and set a $75.00 target price (up previously from $37.00) on shares of AnaptysBio in a research report on Friday, October 13th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. AnaptysBio presently has an average rating of “Buy” and a consensus target price of $88.00.

AnaptysBio (NASDAQ:ANAB) opened at $110.03 on Wednesday. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $116.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. The firm has a market capitalization of $2,560.00 and a P/E ratio of -72.87.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. analysts anticipate that AnaptysBio will post -1.72 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of ANAB. Schwab Charles Investment Management Inc. raised its stake in AnaptysBio by 94.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock worth $465,000 after buying an additional 9,414 shares during the period. Bank of New York Mellon Corp raised its stake in AnaptysBio by 46.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,744 shares of the biotechnology company’s stock worth $473,000 after buying an additional 6,297 shares during the period. Swiss National Bank acquired a new position in AnaptysBio during the 2nd quarter worth approximately $242,000. Teachers Advisors LLC raised its stake in AnaptysBio by 23.4% during the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after buying an additional 1,807 shares during the period. Finally, TIAA CREF Investment Management LLC raised its stake in AnaptysBio by 69.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 13,844 shares of the biotechnology company’s stock worth $331,000 after buying an additional 5,663 shares during the period. 75.48% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/01/17/anaptysbio-inc-anab-short-interest-update.html.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply